Iressa Study in Patients With Salivary Gland Cancer

Phase 2 Completed 37 enrolled M.D. Anderson Cancer Center AstraZeneca · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.

Timeline

Start: 2004-05
Primary completion: 2016-09
Completion: 2016-09

Outcome

Missed primary endpoint

paper No responses were observed. PMID 24585506 ↗

Publications

Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR Jr. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May;37(5):644-9. doi: 10.1002/hed.23647. Epub 2015 Mar 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefitinib	Small molecule	250 mg	Oral